Xanthatin induces G2/M cell cycle arrest and apoptosis in human gastric carcinoma MKN-45 cells

Planta Medica

Volumn 78, Issue 9, 2012, Pages 890-895

  Zhang, Lei ^a,b   Tao, Li ^a   Ruan, Junshan ^a   Li, Weidong ^a   Wu, Yu ^a   Yan, Linggeng ^a   Zhang, Feng ^a   Fan, Fangtian ^a   Zheng, Shizhong ^a   Wang, Aiyun ^a   Lu, Yin ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

apoptosis; Asteraceae; cell cycle; cytotoxicity; gastric carcinoma; xanthatin; Xanthium sibiricum

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLANT MEDICINAL PRODUCT; PROCASPASE 3; PROCASPASE 9; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG; XANTHATIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; PROTEIN PHOSPHORYLATION; STOMACH CARCINOMA; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B; DRUG SCREENING ASSAYS, ANTITUMOR; FURANS; G2 PHASE CELL CYCLE CHECKPOINTS; GENES, P53; HUMANS; I-KAPPA B PROTEINS; INHIBITORY CONCENTRATION 50; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS; TRANSCRIPTION FACTOR RELA;

ASTERACEAE; XANTHIUM SIBIRICUM;

EID: 84862517944     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0031-1298481     Document Type: Article

References (26)

1. Harvey AL. Natural products in drug discovery. Drug Discov Today: 2008; 13 894 901
2. Demain AL, Vaishnav P. Natural products for cancer chemotherapy. Microb Biotechnol: 2011; 4 687 699
3. Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA, Darwiche N. What made sesquiterpene lactones reach cancer clinical trials? Drug Discov Today: 2010; 15 668 678
4. Zhang S, Won YK, Ong CN, Shen HM. Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr Med Chem Anticancer Agents: 2005; 5 239 249 (Pubitemid 40645593)
5. Christensen SB, Skytte DM, Denmeade SR, Dionne C, Moller JV, Nissen P, Isaacs JT. A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells. Anticancer Agents Medicinal Chem: 2009; 9 276 294
6. Kawasaki BT, Hurt EM, Kalathur M, Duhagon MA, Milner JA, Kim YS, Farrar WL. Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach. Prostate: 2009; 69 827 837
7. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci: 2005; 78 431 441 (Pubitemid 41653493)
8. Vasas A, Hohmann J. Xanthane sesquiterpenoids: structure, synthesis and biological activity. Nat Prod Rep: 2011; 28 824 842
9. Little JE, Foote MW, Johnstone DB. Xanthatin: an antimicrobial agent from Xanthium pennsylvanicum. Arch Biochem: 1950; 27 247 254
10. Roussakis C, Chinou I, Vayas C, Harvala C, Verbist JF. Cytotoxic activity of xanthatin and the crude extracts of Xanthium strumarium. Planta Med: 1994; 60 473 474 (Pubitemid 24330782)
11. Ramirez-Erosa I, Huang Y, Hickie RA, Sutherland RG, Barl B. Xanthatin and xanthinosin from the burs of Xanthium strumarium L. as potential anticancer agents. Can J Physiol Pharmacol: 2007; 85 1160 1172 (Pubitemid 351196414)
12. Kovacs A, Vasas A, Forgo P, Rethy B, Zupko I, Hohmann J. Xanthanolides with antitumour activity from Xanthium italicum. Z Naturforsch C: 2009; 64 343 349
13. Takeda S, Matsuo K, Yaji K, Okajima-Miyazaki S, Harada M, Miyoshi H, Okamoto Y, Amamoto T, Shindo M, Omiecinski CJ, Aramaki H. ()-Xanthatin selectively induces GADD45gamma and stimulates caspase-independent cell death in human breast cancer MDA-MB-231 cells. Chem Res Toxicol: 2011; 24 855 865
14. Penissi AB, Vera ME, Mariani ML, Rudolph MI, Cenal JP, de Rosas JC, Fogal TH, Tonn CE, Favier LS, Giordano OS, Piezzi RS. Novel anti-ulcer alpha,beta-unsaturated lactones inhibit compound 48/80-induced mast cell degranulation. Eur J Pharmacol: 2009; 612 122 130
15. Zhang W, Han W, Li Y, Zhang S, Zhao D. [Chemical constituents from Xanthium mongolicum ]. Zhongguo Zhong Yao Za Zhi: 2009; 34 1687 1689
16. Brower V. Back to nature: extinction of medicinal plants threatens drug discovery. J Natl Cancer Inst: 2008; 100 838 839
17. Hehner SP, Heinrich M, Bork PM, Vogt M, Ratter F, Lehmann V, Schulze-Osthoff K, Droge W, Schmitz ML. Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J Biol Chem: 1998; 273 1288 1297 (Pubitemid 28133643)
18. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E, Los M. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat: 2007; 10 13 29 (Pubitemid 46636381)
19. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther: 2004; 3 513 519
20. Siegel RM. Caspases at the crossroads of immune-cell life and death. Nat Rev Immunol: 2006; 6 308 317
21. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell: 2003; 3 421 429 (Pubitemid 38340288)
22. Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer: 2008; 98 523 528 (Pubitemid 351214533)
23. Udayakumar T, Shareef MM, Diaz DA, Ahmed MM, Pollack A. The E2F1/Rb and p 53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy. Semin Radiat Oncol: 2010; 20 258 266
24. Sarkar FH, Li Y. NF-kappaB: a potential target for cancer chemoprevention and therapy. Front Biosci: 2008; 13 2950 2959 (Pubitemid 351589211)
25. Wu Y, Zhou BP. Inflammation: a driving force speeds cancer metastasis. Cell Cycle: 2009; 8 3267 3273
26. Rowinsky EK. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol: 2005; 23 9394 9407